EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges

Bo Pei iD, Shixuan Peng, Weiwei Chen, Lin Lai, Fuxiang Zhou

Technology in Cancer Research & Treatment · 2025-06 · 24

DOI: 10.1177/15330338251334209 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Technology in Cancer Research & Treatment, online erschienen am 06.05.2025. Verfasst von Bo Pei und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi, China. Hauptthemen laut MEDLINE: Cetuximab, Colorectal Neoplasms, Immunotherapy, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: 2020 annual funding for discipline construction, Zhongnan Hospital of Wuhan University, Beijing Bethune Public Welfare Foundation, Natural Science Foundation of Enshi Tujia and Miao Autonomous Prefecture Government.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colorectal cancer (CRC) remains a formidable global health challenge, with the majority of patients exhibiting microsatellite stable (MSS) and proficient mismatch repair (pMMR) tumors that are largely unresponsive to immune checkpoint inhibitors (ICIs). The management of MSS/pMMR CRC remains a clinical challenge due to the intrinsic resistance to ICIs. The innovative strategy of combining cetuximab, an EGFR-targeting monoclonal antibody with immunomodulatory properties, offers a promising strategy to enhance the immunotherapeutic response in MSS/pMMR CRC. This combination therapy is rooted in the complementary therapeutic mechanisms of cetuximab and ICIs, which may synergistically improve overall response rates and durability of response. Although some preclinical and clinical data have suggested additional promising results, there are still some challenges and questions that need to be addressed. Further large-scale, randomized, phase III clinical trials are required to confirm the efficacy and safety of this combination therapy. The ongoing clinical trials evaluating the safety and efficacy of cetuximab-ICI combinations are eagerly anticipated to pave the way for a new era in personalized immunotherapy for MSS/pMMR CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CetuximabColorectal NeoplasmsImmunotherapyAntineoplastic Combined Chemotherapy ProtocolsDNA Mismatch RepairMicrosatellite InstabilityHumansImmune Checkpoint InhibitorsTreatment Outcome

Stichwörter der Autor:innen

EGFRMSS/pMMRcetuximabcolorectal cancercombination therapyimmune checkpoint inhibitorsmechanismsresistance

Substanzen

CetuximabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Oncology, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi, China.
  • Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Provincial Clinical Research Center for Cancer, Hubei Key Laboratory of Tumor Biological Behaviors, Wuhan, China.
  • Department of Oncology, Graduate Collaborative Training Base of The First People's Hospital of Xiangtan City, Hengyang Medical school, University of South China, Hengyang, China.
  • Medical Administration Department, Central Hospital of Enshi Tujia and Miao Autonomous Prefecture, Enshi, China.

ORCID-Profile: Bo Pei

Förderung

  • 2020 annual funding for discipline construction, Zhongnan Hospital of Wuhan University
  • Beijing Bethune Public Welfare Foundation
  • Natural Science Foundation of Enshi Tujia and Miao Autonomous Prefecture Government

Zitieren

APA

Pei, B., Peng, S., Chen, W., Lai, L., & Zhou, F. (2025). Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges. Technology in Cancer Research & Treatment, 24. https://doi.org/10.1177/15330338251334209

Vancouver

Pei B, Peng S, Chen W, Lai L, Zhou F. Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges. Technology in Cancer Research & Treatment. 2025;24. doi:10.1177/15330338251334209

BibTeX
@article{Pei2025,
  author = {Pei, Bo and Peng, Shixuan and Chen, Weiwei and Lai, Lin and Zhou, Fuxiang},
  title = {Combining Cetuximab and Immunotherapy for Treating MSS/pMMR Colorectal Cancer: Current Evidence and Challenges},
  journal = {Technology in Cancer Research & Treatment},
  year = {2025},
  volume = {24},
  doi = {10.1177/15330338251334209}
}
Kostenlos starten →